C4 Therapeutics
(NASDAQ:CCCC)
$5.53
-0.04[-0.72%]
At close: May 24
$5.53
0[0.00%]
After Hours: 7:30PM EDT
Consensus Rating1
Buy
Highest Price Target1
$67.00
Lowest Price Target1
$2.00
Consensus Price Target1
$19.00

C4 Therapeutics Stock (NASDAQ:CCCC), Analyst Ratings, Price Targets, Predictions

C4 Therapeutics Inc has a consensus price target of $19, established from looking at the 33 latest analyst ratings. The last 3 analyst ratings were released from Wells Fargo, Stifel, and Morgan Stanley on May 9, 2024, May 9, 2024, and February 26, 2024. With an average price target of $10 between Wells Fargo, Stifel, and Morgan Stanley, there's an implied 80.83% upside for C4 Therapeutics Inc from these 3 analyst ratings.

Analyst Trend
1
Dec 23
1
Jan
1
1
Feb
1
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
3.0
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Wells Fargo
Stifel
Morgan Stanley
JP Morgan
BMO Capital

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for C4 Therapeutics

Buy NowGet Alert
05/09/2024Buy Now44.67%Wells Fargo
Derek Archila
$7 → $8MaintainsEqual-WeightGet Alert
05/09/2024Buy Now153.16%Stifel
Bradley Canino
$13 → $14MaintainsBuyGet Alert
02/26/2024Buy Now44.67%Morgan Stanley
Terence Flynn
$1 → $8MaintainsEqual-WeightGet Alert
02/23/2024Buy Now135.08%Stifel
Bradley Canino
$12 → $13ReiteratesBuy → BuyGet Alert
01/29/2024Buy Now8.5%JP Morgan
Eric Joseph
→ $6UpgradeUnderweight → NeutralGet Alert
12/13/2023Buy Now117%Stifel
Bradley Canino
$2 → $12UpgradeHold → BuyGet Alert
11/06/2023Buy Now-81.92%Morgan Stanley
Terence Flynn
$3 → $1UpgradeUnderweight → Equal-WeightGet Alert
11/03/2023Buy Now189.33%BMO Capital
Etzer Darout
$18 → $16MaintainsOutperformGet Alert
11/02/2023Buy Now26.58%HC Wainwright & Co.
Andrew Fein
$17 → $7MaintainsBuyGet Alert
10/09/2023Buy Now-63.83%B of A Securities
Chi Fong
$5 → $2MaintainsNeutralGet Alert
08/09/2023Buy Now207.41%HC Wainwright & Co.
Andrew Fein
$25 → $17MaintainsBuyGet Alert
05/30/2023Buy Now80.83%Evercore ISI Group
Gavin Clark-Gartner
$20 → $10MaintainsOutperformGet Alert
05/12/2023Buy Now-45.75%Morgan Stanley
Terence Flynn
$5 → $3MaintainsUnderweightGet Alert
05/08/2023Buy Now352.08%HC Wainwright & Co.
Andrew Fein
$35 → $25MaintainsBuyGet Alert
03/28/2023Buy Now-9.58%B of A Securities
Chi Fong
$11 → $5MaintainsNeutralGet Alert
02/27/2023Buy Now-9.58%Morgan Stanley
Terence Flynn
$6 → $5MaintainsUnderweightGet Alert
02/24/2023Buy Now532.91%HC Wainwright & Co.
Andrew Fein
→ $35Reiterates → BuyGet Alert
02/24/2023Buy Now-9.58%JP Morgan
Eric Joseph
$15 → $5DowngradeNeutral → UnderweightGet Alert
01/03/2023Buy Now62.75%Wells Fargo
Derek Archila
$11 → $9MaintainsEqual-WeightGet Alert
11/08/2022Buy Now98.92%Wells Fargo
Derek Archila
$12 → $11MaintainsEqual-WeightGet Alert
11/04/2022Buy Now171.25%JP Morgan
Eric Joseph
$22 → $15DowngradeOverweight → NeutralGet Alert
10/11/2022Buy Now8.5%Morgan Stanley
Terence Flynn
→ $6Initiates → UnderweightGet Alert
05/09/2022Buy Now532.91%HC Wainwright & Co.
Andrew Fein
$63 → $35MaintainsBuyGet Alert
04/28/2022Buy Now80.83%Credit Suisse → $10Initiates → UnderperformGet Alert
04/18/2022Buy Now370.16%UBS
Colin Bristow
$64 → $26MaintainsBuyGet Alert
04/11/2022Buy Now261.66%BMO Capital
Etzer Darout
$57 → $20MaintainsOutperformGet Alert
03/10/2022Buy Now677.58%JP Morgan
Eric Joseph
→ $43Initiates → OverweightGet Alert
02/10/2022Buy Now352.08%Wells Fargo
Derek Archila
→ $25Initiates → Equal-WeightGet Alert
11/23/2021Buy Now876.49%B of A Securities
Chi Fong
Initiates → BuyGet Alert
10/14/2021Buy Now1111.57%SVB Leerink
Andrew Berens
Initiates → OutperformGet Alert

FAQ

Q

What is the target price for C4 Therapeutics (CCCC)?

A

The latest price target for C4 Therapeutics (NASDAQ: CCCC) was reported by Wells Fargo on May 9, 2024. The analyst firm set a price target for $8.00 expecting CCCC to rise to within 12 months (a possible 44.67% upside). 12 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for C4 Therapeutics (CCCC)?

A

The latest analyst rating for C4 Therapeutics (NASDAQ: CCCC) was provided by Wells Fargo, and C4 Therapeutics maintained their equal-weight rating.

Q

When was the last upgrade for C4 Therapeutics (CCCC)?

A

The last upgrade for C4 Therapeutics Inc happened on January 29, 2024 when JP Morgan raised their price target to $6. JP Morgan previously had an underweight for C4 Therapeutics Inc.

Q

When was the last downgrade for C4 Therapeutics (CCCC)?

A

The last downgrade for C4 Therapeutics Inc happened on February 24, 2023 when JP Morgan changed their price target from $15 to $5 for C4 Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for C4 Therapeutics (CCCC)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of C4 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for C4 Therapeutics was filed on May 9, 2024 so you should expect the next rating to be made available sometime around May 9, 2025.

Q

Is the Analyst Rating C4 Therapeutics (CCCC) correct?

A

While ratings are subjective and will change, the latest C4 Therapeutics (CCCC) rating was a maintained with a price target of $7.00 to $8.00. The current price C4 Therapeutics (CCCC) is trading at is $5.53, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch